Democrats have hit on a new tactic in their long battle with drug companies: challenge patents that they say are deliberate attempts to game the system and box out low-cost, generic competitors. Sen.
JD Supra: Haug Partners Successfully Defends Takeda’s Vyvanse® Patents At Trial Against Generic Challenge
Haug Partners Successfully Defends Takeda’s Vyvanse® Patents At Trial Against Generic Challenge
Nov 2 (Reuters) - Barr Pharmaceuticals Inc said its Barr Laboratories unit began a challenge of patents listed by the U.S. unit of Novartis AG in connection with the generic version of Ritalin LA ...
FiercePharma: GSK, Amneal and Kaleo pull patents from FDA database after FTC challenge
GSK, Amneal and Kaleo pull patents from FDA database after FTC challenge
A recent decision from the U.S. District Court for the District of Delaware highlights an unsuccessful, yet creative Section 101 challenge. This case concerns a generic challenge for the brand-name ...
JD Supra: The FTC’s Challenge to the Listing of Device Patents in the Orange Book: What Challenge?
The FTC’s Challenge to the Listing of Device Patents in the Orange Book: What Challenge?
The biggest outstanding challenge for the generic drug industry moving into the second iteration of its user fee agreement is multiple cycle reviews before approval, Kathleen Uhl, director of the US ...
Generic is the opposite of specific. Generic and specific refer to the identification of a fact. Specific means a fact that has been specified. If you ask for (specify) a pain reliever, aspirin would be a specific pain reliever, while aspirin, acetaminophen, ibuprofen, and naproxen together would be generic pain relievers.